By Admera Health on Feb 20, 2020 1:16:00 PM
Everyone responds differently to certain treatment options. One standard medication may work great for most patients, but for others, there may be little to no benefit, and in some cases, the drug could even be harmful. There are several factors that can contribute to how patients respond to medications, and one of them is genetics. Pharmacogenomics (PGx) combines the study of genetics with the science of drug delivery. PGx testing can help provide additional information on how a patient may respond to medications based on their DNA. These insights can help provide clinical recommendations for certain medications. However, there is not always an easy solution to integrate PGx testing and the reviewing of test results.
That is why Admera Health developed its Clinical Decision Support System (CDSS), RxVision™. Having access to RxVision™ allows healthcare providers to have evidence-based guidance for pharmacogenomics test results from the FDA biomarker list, CPIC, PharmGKB, and FDA approved medication package inserts, which encompasses hundreds of medications.
Admera Health’s RxVision™ provides physicians with digital access, via computer or smart device, to their patients' PGxOne™ Plus reports without requiring an EHR integration. Healthcare providers can navigate the report by analyzing the personalized results of a patient by medication, therapeutic area, and drug interaction. This dynamic portal can also provide the ability to adjust a patient’s medication regime and receive pharmacogenomic information related to that medication on demand.
RxVision™ was designed to be an interactive version of the PGxOne™ Plus report. The healthcare provider is able to view all their patients’ reports in one convenient platform. For each patient specific report, there are four options:
Personalized results are distributed into four quadrants. The medications found in this section encompass the patient’s current medications, as well as, the ICD-10 code specific medications that were requested by the provider.
Full results to view the patient’s complete PGx results for over 50 genes, 200 variants, and 20 therapeutic areas. The sources for all these interactions w ill also be listed in this section.
Search function provides the ability to filter results by of interest, therapeutic area, clinical recommendation, and drug interaction. The provider will be able to see the patient’s genotype and phenotype, as well as any other PGx information available. Also, under the “Search By” medication screen, there is an option to print the medication list (as shown in the image below).
Adding/deleting medications allows the provider to observe if there is any pharmacogenomic information associated with a specific medication, as well as any interactions (drug-drug, drug-alcohol, drug-food, and drug-laboratory), that the provider should be aware of and adjust accordingly.
RxVision™ facilitates peer-to-peer sharing from the referring physician to another. This setting is ideal for physicians in the same clinic or hospital system where they share patients. The left side bar menu contains a section labeled “Physician Referrals,” that once clicked on, the provider can refer another physician by entering that physician’s NPI number.
This new CDSS tool allows providers to view Admera Health’s PGxOne™ Plus test results in an easy-to-use, dynamic format. This post serves as an introduction to a series of RxVision™ blogs, that will touch upon the following topics:
RxVision™ allows healthcare providers to have evidence-based guidance for pharmacogenomics test results from the FDA biomarker list, CPIC, PharmGKB, and FDA approved medication package inserts, which encompasses hundreds of medications.
RxVision™ is able to provide longer-term functionality for users with their PGx results—versus other static PGx reports.
New medications can be checked against available PGx results for gene-drug interactions.
RxVision™ combines drug-drug, drug-food, drug-alcohol, and drug-lab interactions from a medication knowledge-base commonly used in EHRs, along with the patient's pharmacogenomics test results in one central data hub. Thus, eliminating the need to check for drug-drug, drug-food, and drug-lab interactions separately.
This CDSS platform provides physicians the capability to print and share the report with other providers who see the same patient, as well as the ability to refer to other providers, that the patient or physician recommends.
RxVision™ can be used in preemptive PGx workflows in addition to reactive PGx workflows.
Follow the steps below to setup your RxVision™ account and access the CDSS platform.